New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
13:25 EDTJNJ, JNJ, SNN, SNN, SYK, SYK, ZMH, ZMHLeerink's medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Newitter provides his perspective on new products, technologies and key focus topics and issues to be covered at the upcoming American Academy of Orthopedic Surgeons (AAOS) 2014 Conference in New Orleans on March 11-15 on an Analyst/Industry conference call to be held on March 6 at 2 pm.
News For JNJ;SNN;SYK;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
10:15 EDTSYKMarathon Patent unit gets favorable early ruling of infringement of '260 patent
Marathon Patent Group (MARA) announced that on July 1, in the patent infringement action filed by its wholly-owned subsidiary, MedTech Development Deutschland GmbH involving the patent EP 1 104 260 B2 the Munich District Court of Germany expressed in its preliminary opinion that the following defendants, Joline GmbH & Co. KG, Signus Medizintechnik GmbH and PanMedical, infringe the '260 patent. The '260 patent had previously been accused of invalidity by Stryker GmbH & Co. KG (SYK). In a nullity hearing held June 19, the five-judge panel at the Federal Patent Court, after carefully considering all facts and arguments brought by Stryker, deliberated and returned with the unrestricted verdict that "All claims are valid."
July 1, 2015
16:33 EDTJNJGilead submits NDA to FDA for single tablet regimen for HIV containing R/F/TAF
Gilead Sciences (GILD) announced that it has submitted a New Drug Application, or NDA, to the FDA for an investigational, once-daily single tablet regimen that combines Gileadís emtricitabine 200 mg and tenofovir alafenamide, or TAF, 25 mg with rilpivirine 25 mg, or R/F/TAF, from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naÔve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen. A Priority Review voucher acquired from Knight Therapeutics in November 2014 was submitted to the FDA along with the R/F/TAF NDA. Under the Prescription Drug User Fee Act, or PDUFA, the anticipated target action date for the R/F/TAF NDA is six months after the FDAís acceptance of the filing. TAF is a novel, investigational nucleotide reverse transcriptase inhibitor, or NRTI, that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gileadís Viread, as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials in combination with other antiretroviral agents. In addition to R/F/TAF, two other TAF-based HIV treatments are also under FDA review.
June 30, 2015
16:56 EDTZMHKKR 2006 Fund reports 14.8% stake in Zimmer
Subscribe for More Information
16:39 EDTZMHLVB Acquisition Holding reports 14.8% stake in Zimmer
June 25, 2015
10:00 EDTZMHOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:32 EDTZMHZimmer downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Zimmer to Hold saying uncertainty over 2016 earnings potential following the Biomet acquisition is likely to linger for several quarters. Brean sees little room for multiple expansion pending greater clarity.
June 24, 2015
13:14 EDTZMHZimmer trading resumes, shares up 96c to $113.66
13:11 EDTZMHZimmer Biomet sees 2015 constant currency revenue growth 1.5%-2.0%
Subscribe for More Information
13:09 EDTZMHZimmer announces completion of Biomet acquisition
Subscribe for More Information
13:00 EDTZMHZimmer trading halted, pending news
Subscribe for More Information
11:54 EDTZMH, SNNSmith & Nephew to acquire Zimmer Unicondylar Knee system in U.S. market
Subscribe for More Information
11:32 EDTZMH, SNNZimmer required by FTC to divest assets as condition of Biomet acquisition
Subscribe for More Information
June 23, 2015
10:00 EDTSNNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:30 EDTSNNSmith & Nephew upgraded to Buy from Neutral at UBS
Subscribe for More Information
June 22, 2015
07:43 EDTSYKStryker management to meet with Deutsche Bank
Meeting to be held in Paris on June 22 hosted by Deutsche Bank.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use